Novo Nordisk: From Insulin to Ozempic

In one sentence: A pharma giant that bet a full century on a single therapeutic direction — metabolic health — first as the insulin-and-diabetes company for 100 years, and then, out of one scientist's repeatedly-almost-cancelled side project, growing Ozempic and Wegovy to become the most valuable company in Europe (passing LVMH). Its two great anomalies: first, revenue is wildly concentrated — 85% in metabolic disease, only the world's 20th-largest pharma by revenue yet the 15th-largest company on Earth by market cap; second, it is owned and controlled by a non-profit foundation — and it was precisely that foundation refusing to sell the company in 2004 that made GLP-1 possible at all. In David's words: "This is the Hermes of the pharma industry."

The Company on One Page

Founders & Key People

August Krogh: a Nobel laureate who didn't study humans

Krogh is the founder named in the frontmatter, but he was neither a physician nor even a human biologist — he was an animal physiologist who won the 1920 Nobel for animal research. David's favorite sidebar: Krogh's PhD advisor at the University of Copenhagen was Christian Bohr — the father of Niels Bohr, father of atomic physics and a major Manhattan Project contributor. "There must have been something in the water in Copenhagen at that time."

What actually pulled Krogh into this history was personal: the same summer he won the Nobel (1920), his wife Marie was diagnosed with diabetes. On a delayed 1922 US lecture tour he heard about the Toronto insulin breakthrough from Joslin, went north to learn it, brought the Scandinavian rights home, lent his own lab, then stepped back to his own research as a foundation board member. He also delivered the other half of the origin quarrel — when the Pedersen brothers stormed out to make insulin themselves, Krogh said "but you're not capable of that," goading them into a 65-year rivalry.

Marie Krogh and Hans Christian Hagedorn

Marie was Denmark's first woman with a doctorate in medicine, a practicing physician who diagnosed her own disease and wrote the letters that carried the Toronto news home and connected Hagedorn. Hagedorn had been Marie's doctor — the best young endocrinologist in Copenhagen — who resigned his medical post to run Nordisk day to day. He stamped his own name onto the product: NPH = Neutral Protamine Hagedorn — and argued Nordisk's Supreme Court patent case himself, and won. "It tells you what you need to know about him." The other co-founder, August Kongsted, owner of the Lion's Chemical Factory, supplied the commercial mind this scientist-plus-physician combo lacked.

The Novo Nordisk Foundation: the shareholder that actually matters

• Control and economics are split: through Novo Holdings, the foundation holds 77% of the voting shares and 28% of the economic shares of Novo Nordisk. "No shareholder activism in this company, or at least no one's effective in doing so."
• Growth is not in the mission: the foundation's formal objectives are stability (keep Novo Nordisk alive for the long run) plus supporting scientific and humanitarian causes — growth is explicitly not one of them. It became one of the great growth companies anyway.
• The largest charitable foundation in the world: Novo Holdings' AUM / endowment is about $120B — more than 2x the #2 Gates Foundation. Ben's sober footnote: most of that $120B is just its Novo Nordisk stock, roughly a quarter of the market cap — "it's not like they spat off $120B in cash." But it has also become one of the most active life-sciences investors in the world, holding venture stakes in 80+ companies.
• This structure is common in Denmark: Lego and Maersk are the same (largely a high-tax generational-transfer mechanism).
• The company's stated mission is to eradicate Diabetes. The 2014 chief medical officer's line still stops you cold:

"We feel a responsibility for trying to prevent or eradicate Diabetes. If that means the dissolution of Novo Nordisk, that would be fine."

Lotte Bjerre Knudsen: the lone believer behind GLP-1

Joined Novo in 1989 (the merger year), fresh out of undergrad — into the enzyme division of all places — then moved to diabetes and the compound-screening group. She staked her whole career on a molecular path the entire industry had abandoned: GLP-1 stays active in the body for only ~5 minutes before it's metabolized, so everyone hit the wall and gave up. Management gave her an ultimatum — get a real drug candidate into the pipeline within a year, or the program dies. She grafted a fatty acid onto GLP-1 to make liraglutide, with a 13-hour half-life (versus 2.5 minutes for straight GLP-1). She later pushed the weight-loss indication forward against the company's own stated position that weight loss was no business at all. Asked whether she'd gotten rich off inventing GLP-1s, her answer was very Danish:

"I've never asked for a raise in my life. I'm a socialist, but look at what we've done for the world."

The Playbook

Each entry: origin story → insight → effect.

1. Extreme focus on one disease, one metabolic domain

• Story: For a full 60 years (1920–1980) this was a decidedly un-sexy market — diabetes then meant mostly childhood Type 1: miraculous for the world, but hardly a colossal commercial prize. The real ignition was "we all got fat": Type 2 quadrupled from 1980 to 2016. As Munger put it, there aren't many times in a lifetime you know you're right and know the investment will work — you may only understand it five years after you buy it.
• Insight: Find a big enough market, target it, and stay on it for decades or a century (Sequoia / Don Valentine's "target big markets"). The foundation grasped it before management did: this wasn't a service they were doing for the world — it was one of the most important markets in the world.
• Effect: 85% of revenue in metabolic disease; #20 by revenue yet #15 by market cap — a pure "multiple" story.

2. Foundation control = a long-termism moat (the master key)

• Story: Through the 1990s–2000s, management was forever seeking a buyer. In 2004 they lined up a merger with Serono, the operating board on board, needing only the foundation's stamp. The foundation's charter has a "convincing business argument" clause — any sale must be proven a necessary precondition for staying competitive internationally. Management pitched it confidently; the foundation asked, "have you looked at our revenue and profit growth over the last 15 years? Are you really, really telling me we need to do this?" After two meetings, they blocked it. The mirror image of OpenAI: here the foundation insisted the company stay an independent commercial entity.
• Insight: Ownership structure is destiny. In good times, public or private hardly matters; the real question is whether you can hold your direction when catastrophe — or temptation — arrives.
• Effect: "If this ownership structure were not in place, we would not be doing this episode today." Without that refusal the company gets rolled up, and GLP-1 never grows out of it.

3. A local nemesis writes innovation into the DNA

• Story: The Pedersen brothers slammed the door, founded Insulin Novo, and fought Nordisk head-to-head for 65 years in mutual loathing. Ben's analogy: "It's Ferrari and Lamborghini. It's Aldi and Trader Joe's. It's Adidas and Puma."
• Insight: Plant a close, strong rival early and you infuse competitive pressure into a company's blood for decades. Without that bitter enemy down the street, Nordisk might not have moved so fast, and Novo wouldn't have been forced to build its own science.
• Effect: Two tiny firms in an unlikely small country ended up leading maybe the most important drug development of the 20th century.

4. The scrappy upstart's counter-positioning

• Story: Novo couldn't just clone Nordisk (which had a Nobel scientist, Denmark's best endocrinologist, and Toronto's blessing). It used the Pedersens' engineering to make shelf-stable liquid insulin — no boiling, no dissolving — and, being far more efficient, launched it at half price. The ivory-tower Nordisk scientists were aghast ("marketing insulin at half price — is this stuff even safe?"), to which the Pedersens said, "yeah, whatever, we're going to crush you."
• Insight: Counter-positioning belongs to the takeoff phase and to challengers; incumbents almost never do it (Ben: "Incumbents don't really counter position, startups counter position").
• Effect: The two men once told they were "not capable" built the larger company (62% of the merger).

5. A protein/peptide-engineering platform — "protect the molecule"

• Story: For decades both Novo and Nordisk drilled the same craft: finely tuning how a single injection is absorbed and how long it acts inside the body's complex environment — NPH, Lente, MC Insulin — chasing longer duration and higher purity. Liraglutide's mechanism is that craft extended: a grafted fatty acid makes the molecule bind albumin, a big blood protein — "like a big truck bouncing down a small highway," too large to be filtered by enzymes or cleared by the kidney.
• Insight: This is nothing like software's "add some code, ship a feature." It's decades of accumulated know-how in how molecules degrade in the body — Ben calls it "the Novo magic."
• Effect: The same competency later produced Rybelsus — a once-a-day oral semaglutide (empty stomach, no food for 30 minutes after), an engineering feat.

6. Conviction on science the whole industry had abandoned

• Story: GLP-1 vanished in five minutes; academia and industry all but pronounced it dead. Even "the world's most focused diabetes company" nearly quit — hence Lotte's one-year ultimatum.
• Insight: If cracking it would genuinely help people, keep pushing through pressure inside and out. Long horizons plus focus were exactly what no one else was betting on this timescale — Semaglutide didn't come from nowhere; it stands on all the liraglutide work since the early 1990s.
• Effect: liraglutide → semaglutide → an entire GLP-1 franchise, turning an insulin company into a GLP-1 company.

7. One molecule, many indications = compounding expansion

• Story: One molecule, liraglutide, became Victoza (diabetes) + Saxenda (weight loss); one molecule, semaglutide, became Ozempic + Wegovy + Rybelsus; and the same molecule is now in trials for cardiovascular disease, Alzheimer's, and kidney disease. Because the half-life is so long, it reaches tissues normal GLP-1 never would, with signs of benefit.
• Insight: Ben's Humira analogy — AbbVie's Humira won 11 indications and did $200B in lifetime sales. "You actually don't need a deep pipeline if you have a drug you can be profitable on, with few competitors, a patent that gives you room, a brand, and approval across large-population indications." (Off-label prescribing at doctors' discretion amplifies early demand.)
• Effect: One blockbuster can make it "not matter how deep or diverse your pipeline is — you just win" for a decade-plus.

8. Delivery-form innovation is a way to renew the patent

• Story: Novo invented the insulin pen in the 1980s; Nordisk focused on pumps. GLP-1 went from once-daily to once-weekly to an oral pill. Patents cover not just the molecule but the delivery mechanism.
• Insight: Introduce a newer pen and doctors tend to say "that's what we should be prescribing now" — a brand accretes around the latest patented form, even if it's barely better than the old one.
• Effect: Like insulin's century, GLP-1 becomes ever-stacking waves of patentable innovation (Semaglutide's patent runs to 2032, then CagriSema starts a new cycle).

9. Disrupt yourself just in time — right before insulin collapses

• Story: The insulin business was gutted in five years by three forces: post-scandal price caps, biosimilars (the "generics" of biologic drugs), and GLP-1 cannibalizing demand. Eli Lilly's insulin went from $700M (1999) to $2.6B for two products (2017) — the bigger the prize, the more worth invading the castle.
• Insight: Ben, borrowing from the NVIDIA episode — "moats are only sufficient if the castle is sufficiently lame to invade."
• Effect: Was it courageous self-disruption or just reading the writing on the wall? Both hosts lean toward: the timing lining up was a happy accident.

10. Align incentives to the long term, not the stock price

• Story: Executives and board members get no stock options — but they are required to hold the stock. "Sticks, not carrots," the logic close to Berkshire (own the liability rather than pocket free equity). Employee comp is reportedly below peers, too.
• Insight: Incentives untethered from a three-to-five-year stock window stretch people's time horizon; add Denmark's more socialist culture (Lotte's "I'm a socialist") and you attract missionaries over mercenaries.
• Effect: A reasonable narrative — it was precisely that long horizon and focus that let decades of GLP-1 grind finally bear fruit, when no one else invested on that timescale.

11. Mass-market, relatively cheap drugs — against the industry grain

• Story: For two decades pharma tilted toward specialty/orphan drugs — populations of a few hundred thousand or even 300 people, priced in the millions per dose. Part of the reason is the "better than the Beatles" problem (Alex Telford): a new drug must beat existing therapies to win approval, so common diseases with "good enough" treatments get harder to justify.
• Insight: Novo went the other way — into diabetes and obesity, diseases afflicting hundreds of millions — "only" a few thousand dollars a dose but covering enormous populations, mostly chronic conditions taken for life (annual recurring revenue).
• Effect: It concentrated in an area everyone else shied away from — and ended up with the largest addressable market ever (US ~40% obese, 500M+ worldwide).

12. Pharma is the venture business — winners subsidize every failure

• Story: A single approved drug averages $2.3–2.5B (vs $40M in 1953, inflation-adjusted); of 100 drugs entering clinical development, ~10 reach market and 1 provides half the profits; most approved drugs never earn back their R&D. Phase 3 is the expensive gate, 29% of a drug's R&D spend.
• Insight: This is venture capital with a zero or two added — winners must fund all the failures, and payoffs come a decade-plus later ("There's no MVP in Semaglutide").
• Effect: Only firms large and capitalized enough can carry the pipeline — hence relentless consolidation; yet Novo, through focus and patience, posts ROIC well above the industry median.

13. A rare brand breakout

• Story: Pharma usually has no brand; Ozempic is the exception — front page of the NYT, a Jimmy Kimmel joke at the Oscars, nicknamed "Vitamin O / Oz." Ben first assumed Mounjaro was "a crappy knockoff" (it's actually a similarly effective, similar-mechanism drug). Weight loss also carries a tight feedback loop and "walking billboard" word-of-mouth (drop a few pounds and everyone sees it).
• Insight: In a patent-driven industry, Ozempic genuinely has brand power — though David insists it's word-of-mouth marketing rather than a true network economy.
• Effect: The brand itself becomes extra distribution leverage, pushing demand fuller and supply tighter.

Moat Analysis (the 7 Powers framework)

7 Powers is Hamilton Helmer's strategy framework (7 Powers: The Foundations of Business Strategy): seven structural advantages that let a company sustain differential returns versus rivals. Acquired runs every company through the checklist; below is this episode's verdict. In pharma, the ever-blinking red light is Cornered resource — this is a patent-driven industry.

Bull & Bear (as of recording)

• Bull (David): Are GLP-1s the next super cycle? If yes, that's the bull case. Barriers to entry are very high; Eli Lilly (Tirzepatide → Mounjaro / Zepbound) and others will share the market, but demand is so vast that "there's room for everybody," and every unit gets pulled off the shelf. Semaglutide plus follow-ons like CagriSema could match or exceed Humira ($200B lifetime).
• Bear (Ben): For any reason — health risk, insufficient efficacy, whatever — it doesn't play out long term, or not on insulin's multi-decade timeline. Known "boogeymen in the closet": weight rebound after stopping; ~1-in-6 patients discontinuing over side effects; ~68% rolling off within a year; and early studies suggesting more lean-muscle loss on GLP-1 (~40% vs ~25% via diet-and-exercise). Suicidal ideation was a narrative for a while, but current research and regulators haven't flagged it as a real risk.

Grading (synthesis): This is one of Acquired's rare "almost every Power lights up" companies — patent + scale + switching costs stacked with a rare brand. The real moat question isn't whether but for how long: at least through the patent cliff around 2032; beyond that depends on whether GLP-1 becomes, like insulin, wave upon wave of patentable innovation. Industry-wide ROIC has declined for decades (~13%, in line with trucking / broadcasting), but company-level variance has widened — good companies get better, bad ones worse — and Novo sits at the top of that spread.

Deep Cuts (Novo Nordisk itself)

• Where the names come from: Nordisk = Nordic Insulin; Novo is the product of the Pedersens' parting shot "we will show you" — Insulin Novo. Two Augusts anchor the founding — Krogh and Kongsted; two Larses anchor the modern CEO chair — Sorensen and Jorgensen. (When David googled "Lars Jørgensen," results one through six were all the University of Kentucky swimming coach of the same name; only #7 was the CEO of the world's 15th-largest company — "that is how underappreciated this company is.")
• Insulin used to be solid tablets: early patients had to dissolve solid tablets in boiled, sterilized water, draw the solution into a glass syringe with a big needle, and inject — with no glucose meter, "you're throwing darts." Novo's liquid insulin was aimed squarely at this.
• The wartime gray zone: Novo's fortunes exploded under Nazi occupation because the Nazis ordered it to expand and supply all of Europe — "an evil person commanding me to make more life-saving drugs and distribute it to more people is fine. It's the other things they command you to do that are not fine." Afterward the Danish state clawed back most of the wartime profits.
• Novo invented the insulin pen (1980s), while Nordisk led on pumps — the rivalry played out in delivery form, too.
• Where Novozymes came from: post-war, Novo added a "second leg" in enzymes (laundry detergent enzymes, etc.), a capital-intensive, low-margin business; it was spun out as Novozymes in 2000, still controlled by Novo Holdings.
• Brenham's line (at the merger, describing the combined company as a specialized little guy):

"a specialized dwarf that will probably create a certain fuhrer on the global stage."

[Note: the mirror reads "fuhrer"; from context this is almost certainly a transcription of "furor" (uproar). Recorded verbatim with this annotation.]

• Rybelsus's odd rules: oral semaglutide must be taken on an empty stomach with no food for 30 minutes after, and is slightly less effective than the injectable — but getting a GLP-1 to survive the stomach and reach the bloodstream orally is itself an engineering marvel.
• One molecule carries most of the company: at recording, 51% of revenue is diabetes GLP-1, 18% obesity GLP-1 (69% combined from semaglutide / liraglutide), 22% Insulin, 9% other (rare diseases, hemophilia). Gross margin ~84% — higher than software, ~10 points above a typical big pharma.

Era & Industry Trivia (the tangents worth keeping)

• The insulin discovery and the Banting/Best Nobel affair: In 1921 Toronto, Banting and Best extracted insulin from dog pancreases and injected it into dying patients, producing "miraculous" recoveries — but insulin was never a cure, only a "lease": another injection every few hours. Bizarrely, the purification process was forgotten, then re-derived by someone else, then pieced back together with the original notes before it worked at scale. The 1923 Nobel went to Banting and lab head Macleod but skipped Best, the student who did the actual work — years later the Nobel Committee all but admitted the mistake. And the nominator was August Krogh, future founder of Novo Nordisk.
• The manufacturing barrier of peptide/biologic drugs: early insulin was throttled by the supply of dead animal pancreases — 8,000 pounds of pancreatic glands from 23,500 animals to make a single pound of human insulin; even by 1980 it took one million animals a year to treat just 30,000 patients. That scarcity is why Type 2 was once called "non-insulin-dependent diabetes" — not because insulin didn't help, but because there simply wasn't enough of it. The ceiling lifted only in 1980 when Genentech + Eli Lilly made recombinant human insulin (also the first genetically engineered drug ever) — Genentech's IPO that fall was the largest venture-backed IPO to date, eclipsed two months later by Apple.
• The Danish foundation-control model, echoed by IKEA and Rolex: this episode names Lego and Maersk as fellow Novo Nordisk-style structures — operating companies controlled by a charitable/family foundation, largely a high-tax generational-transfer mechanism, whose payoff is immunity to shareholder activism and the ability to operate on decade-scale horizons. Zoom out and this is a whole species: the Netherlands' IKEA (controlled by the Stichting INGKA Foundation) and Switzerland's Rolex (wholly owned by the Hans Wilsdorf Foundation and never public) run on the same logic — writing "don't get pushed around by capital markets" into the ownership structure itself.
• GLP-1's path from diabetes to weight loss was a chain of accidents: the first marketed GLP-1 (Byetta) came from Gila monster venom — in 1995 Daniel Drucker had a venomous lizard shipped from Utah to study its venom; and Drucker's lab was at… the University of Toronto (he even owns glucagon.com for extra credibility), bringing the story full circle to insulin's birthplace a century earlier. The weight-loss effect was first noticed by Lotte in animal trials — high-dose liraglutide made rats stop eating, even starve themselves — and yet, as of 2005, Novo's own CEO's official position was:

"Obesity is primarily a social and cultural problem... There is no business for Novo Nordisk in that area."

Just two years later, the company put high-dose liraglutide into human weight-loss trials.

• America's drug-pricing maze: a drug runs from manufacturer → distributor (McKesson / Cardinal Health) → pharmacy (CVS, etc.) → patient, with insurers, employers, and — crucially — the PBM (Pharmacy Benefits Manager) wedged in. The three big PBMs (Express Scripts, CVS Caremark, and UnitedHealth's OptumRx) cover ~80% of the market and gatekeep whether drugs reach patients at all. Eli Lilly has publicly claimed rebates ran to 75% of insulin's sticker price — "the sticker price is not the price." Ben quotes a source calling the rebate system "a game of hide the sausage." Same drug: US Ozempic >$1,000/month, Canada $147, UK $93.
• The dark history of weight-loss drugs and the "10% magic line": from 1970s amphetamines (speed) to 1990s Fen-Phen (a combination with speed, taken by ~6 million Americans, causing major cardiovascular damage), four decades of weight-loss drugs were either dangerous or useless, scaring off the FDA and the whole industry. The consensus: a market exists only if a drug can safely take off 10%+ of body weight — otherwise it rounds to zero. Saxenda stalled below ~8%; only semaglutide's 15%+ truly cleared the line. Before 2020, global weight-loss-drug sales were just $744M.
• The macro picture of health spending: US healthcare rose from 5% of GDP in 1960 to 17–18% today. Yet pharma is only **13% of healthcare revenue — hospitals 28%, professional services (doctors' offices) 26%, health-insurance administration 8%. Ben's zinger: "health insurance in the US is not insurance. It's access.**" The ones actually taking risk in the arena are pharma — "pharma are the guys in the arena."

Cross-domain Notes

No strong overlap with the PH (geopolitics) domain — pharma / public health and geostrategy are essentially orthogonal, and no links are forced. Three weak resonances worth noting: (1) the "foundation control → long time horizon → resistance to capital-market short-termism" governance mechanism is structurally the same lens the PH domain applies to "who really holds the long-term wheel, and who can control their own destiny when catastrophe hits" — a useful business-domain comparison sample; (2) this episode's dissection of the PBM/insurance middle-layer shadow economy (more intermediaries → more distorted demand signals → the actual risk-taking innovator gets stigmatized) shares its incentive-structure lens with the PH domain's "complex" critiques; (3) the "insulin century → GLP-1 super cycle" pattern of decade-scale, wave-upon-wave technology stacking rhymes with the PH domain's preference for long-horizon judgment. If Acquired's Eli Lilly / Genentech / TSMC episodes get ingested later, this episode's recombinant DNA and GLP-1 race become natural connectors.

Pages Worth Creating

• Entities: august-krogh (founder page: animal physiologist, Nobel laureate, Novo Nordisk's named founder), Costco：会员费买来的信任机器 (another foundation/family-controlled, long-horizon, focus-driven comparison company; Acquired has a dedicated episode)
• Concepts: 7 Powers 护城河框架 (Hamilton Helmer's framework, Acquired's standard analytical toolkit), 家族与基金会控制 (the Danish foundation-ownership model: Novo / Lego / Maersk / IKEA / Rolex)
• Themes (longer term): pharma as "venture capital with zeros added" (winners subsidizing failures, blockbuster economics); the US healthcare value chain and the PBM shadow economy

Source · acquired